|1.||Pizzo, Salvatore V: 8 articles (08/2009 - 03/2002)|
|2.||Wahl, Miriam L: 7 articles (05/2007 - 01/2002)|
|3.||Folkman, Judah: 6 articles (10/2011 - 12/2002)|
|4.||Cirone, Pasquale: 6 articles (05/2006 - 07/2003)|
|5.||Chang, Patricia L: 5 articles (05/2006 - 07/2003)|
|6.||Indraccolo, S: 5 articles (10/2003 - 01/2001)|
|7.||Sacco, M G: 5 articles (10/2003 - 05/2000)|
|8.||Vezzoni, P: 5 articles (10/2003 - 05/2000)|
|9.||Scanziani, E: 5 articles (10/2003 - 05/2000)|
|10.||Cao, Y: 5 articles (01/2003 - 05/2000)|
11/01/2002 - "The therapeutic efficacy of angiostatin against weakly- and highly-immunogenic 3LL tumors."
01/01/2004 - "These studies demonstrate the feasibility of using AAV anti-angiogenic gene therapy as a cancer treatment modality and suggest that the optimal anti-tumor efficacy of angiostatin following gene transfer may be limited to a narrow dose range."
01/01/2004 - "The aim is to shed light on areas in which more research is needed with respect to angiostatin and other anti-angiogenic agents and the microenvironmental conditions that affect their activities, in order to develop improved therapeutic strategies for diabetic cancer patients."
11/01/2000 - "These data suggest that low pH(e) plays a role in the relative specificity and efficacy of angiostatin for tumor neovasculature and indicate roles for both pH(e) and pH(i) in the mechanism of angiostatin action. "
11/01/2002 - "Our current study evaluated whether anti-tumor immune response could also potentiate the therapuetic efficacy of another antiangiogenic drug, angiostatin. "
05/15/2007 - "MAb3D5AB1 disrupts tube formation and decreases intracellular pH in endothelial cells exposed to low extracellular pH. Neither angiostatin nor MAb3D5AB1 showed an antiangiogenic effect in the corneal neovascularization assay; however, both were effective in the low-pH environment of the chicken chorioallantoic membrane assay. "
07/01/2012 - "Obtained data shows the promising potential of development of medications based on angiostatin K1-4,5 for suppression of corneal neovascularization and for treatment of diseases associated with corneal ulceration."
01/01/2007 - "The area of corneal neovascularization was significantly lower in eyes injected with rAAV-angiostatin (p<0.01) than in eyes injected with the control virus. "
01/01/2005 - "Because corneal cells generate angiostatins, use of human angiostatins may be a means of treating abnormal corneal neovascularization without the risk of side effects."
08/01/2002 - "This appears to be the first evidence of biologically induced regression of corneal neovascularization, and the first direct demonstration of angiostatin-induced regression of neovascularization in any tissue."
|3.||Neoplasm Metastasis (Metastasis)
01/01/2008 - "Our results suggest that the biological activity of angiostatin as a putative metastasis inhibitor may be in part the result of nm23 inhibition and that the production, lyophilization, packaging or storage of commercial angiostatin leads to the alteration of its biological activity against NDPK-B. "
11/14/2003 - "Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity."
01/01/2003 - "Angiostatin prolongs the survival of mice with leptomeningeal metastases."
03/19/2001 - "Angiostatin, a circulating inhibitor of angiogenesis, was identified by its ability to maintain dormancy of established metastases in vivo. "
01/01/2000 - "Angiostatin markedly inhibits the growth and metastasis of LA795 cells on T739 mice and no obvious side effects of angiostatin were found during the treatment."
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
08/01/2002 - "Experimental study of gene therapy with angiostatin gene in pancreatic cancer."
08/28/2005 - "Angiostatin does not directly inhibit human pancreatic cancer cell proliferation and growth in vitro, but it inhibits endothelial cell growth in vitro. "
08/28/2005 - "To observe the biologic behavior of pancreatic cancer cells in vitro and in vivo, and to explore the potential value of angiostatin gene therapy for pancreatic cancer. "
08/28/2005 - "Angiostatin inhibits pancreatic cancer cell proliferation and growth in nude mice."
08/01/1998 - "We have previously shown that the human pancreatic cancer cell line ASPC-1 produces enzymatic activity capable of generating angiostatin. "
01/01/2003 - "For instance, intraarticular application of the angiostatic molecule angiostatin reduces the severity of collagen-induced arthritis in mice. "
03/01/2002 - "To determine the efficacy of local therapy with human angiostatin gene in murine collagen-induced arthritis (CIA). "
09/01/2005 - "These results indicate that the HIV vector-mediated expression of angiostatin efficiently inhibits the progression of collagen-induced arthritis. "
09/01/2005 - "Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice."
07/01/2005 - "AAV-vector-mediated local expression of angiostatin efficiently inhibited the development of collagen-induced arthritis in the treated joint. "
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Tissue Inhibitor of Metalloproteinase-2
|8.||glucuronyl glucosamine glycan sulfate (Vessel)
|9.||pigment epithelium-derived factor
|10.||Angiogenesis Inducing Agents (Angiogenesis Factor)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)